Tick-borne Encephalitis, FranceCoMTBEVNCT07191223
Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in France
An observational study of Tick-borne Encephalitis, France, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Tick-borne encephalitis is a relatively rare disease (approximately 35 cases diagnosed per year), but most cases (86%) are due to contamination in France via a tick bite. Of the 71 cases reported over two years (May 2021 to May 2023), 94% of patients were hospitalized. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Tick-borne Encephalitis, France
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 16 Feb 2024to 16 Feb 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Doctoral student or in training and practicing in France
Who may be able to join
- Be a doctoral student or in training
- Practice in France
- Agree to participate in the survey.
Who cannot join
- Refusal to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service des maladies infectieuses et tropicales - CHU de Strasbourg - France
Strasbourg, 67091
Yves HANSMANN, MD, PhD, 33 3 69 55 09 78, yves.hansmann@chru-strasbourg.fr
Yves HANSMANN, MD, PhD
About this study
Official title: Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners and Specialists in Endemic Areas and Outside Endemic Areas in France
Tick-borne encephalitis is a relatively rare disease (approximately 35 cases diagnosed per year), but most cases (86%) are due to contamination in France via a tick bite. Of the 71 cases reported over two years (May 2021 to May 2023), 94% of patients were hospitalized.
It is therefore important to consider and diagnose at the first signs to ensure appropriate follow-up and also to implement primary prevention in endemic/at-risk areas.
- Conditions
- Tick-borne Encephalitis, France
- Keywords
- Tick-borne encephalitis, tick bite
- Medical subject headings
- Encephalitis, Tick-Borne, Tick Bites
What is being measured
The primary outcome is the main question the study is designed to answer.
Tick-borne meningoencephalitis knowledge score
Measured: Up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2025
- Study start16 Feb 2024
- Primary completion16 Feb 2026 (estimated)
- Study completion16 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tick-borne Encephalitis, FranceStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07191223
- Sponsor's protocol ID
- 9141
- Acronym
- CoMTBEV
- Status last verified
- Mar 2025
- First submitted
- 25 Mar 2025
- Last updated
- 24 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners and Specialists in Endemic Areas and Outside Endemic Areas in France
- ClinicalTrials.gov ID
- NCT07191223
- Acronym / sponsor ID
- CoMTBEV / 9141
- Conditions
- Tick-borne Encephalitis, France
- Keywords
- Tick-borne encephalitis, tick bite
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 16 Feb 2024 (actual)
- Primary completion
- 16 Feb 2026 (estimated)
- Study completion
- 16 Feb 2026 (estimated)
- First posted
- 24 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tick-borne encephalitis is a relatively rare disease (approximately 35 cases diagnosed per year), but most cases (86%) are due to contamination in France via a tick bite. Of the 71 cases reported over two years (May 2021 to May 2023), 94% of patients were hospitalized.
It is therefore important to consider and diagnose at the first signs to ensure appropriate follow-up and also to implement primary prevention in endemic/at-risk areas.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Doctoral student or in training and practicing in France
Key inclusion criteria (3 listed)
- Be a doctoral student or in training
- Practice in France
- Agree to participate in the survey.
Key exclusion criteria (1 listed)
- Refusal to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Tick-borne meningoencephalitis knowledge score
Time frame: Up to 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2025.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tick-borne Encephalitis, France, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yves HANSMANN, MD (33 3 69 55 09 78, yves.hansmann@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tick-borne meningoencephalitis knowledge score (time frame: Up to 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2025.